Pentixapharm Holding AG / Key word(s): Study/Research Update
Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial (news with additional features)
26.09.2025 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Additional features:
File: 20250925 – Pentixapharm PR IIT Nantes EN FINAL
26.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at http://www.eqs-news.com
This news is powered by Ad Hoc News 
